Merck & Co., Inc.

Merck & Co., Inc. (MRK) — Investment Memo

🐂 The Bull Case (Warren's voice)

The appeal here isn't the science—it's the sociology of medical necessity.

• The Ultimate Toll Bridge: Merck doesn't sell "products"; it sells survival. When a physician prescribes a patented Merck drug, the price is secondary to the outcome. That is the definition of pricing power.
• The Animal Health Hedge: While human pharma is a volatile game of "hit or miss," the Animal Health segment is a steady, recurring cash machine. It's less regulated, has longer product lifecycles, and provides a floor to the valuation.
• Institutional Efficiency: They have mastered the art of the "strategic alliance." By sharing the R&D burden with partners like Daiichi Sankyo, they offload some of the binary risk while retaining the right to harvest the rewards.
• Attractive Entry: This becomes a Berkshire-style "fat pitch" only if the market panics over a short-term clinical failure or a temporary regulatory headline, driving the price down to a level where the dividend yield alone compensates for the patent risk.

🐻 The Bear Case (Charlie inverts)

"Show me where I'll die and I won't go there."

• The Keytruda Monolith: The business is dangerously concentrated. Keytruda is a miracle drug, but it's also a single point of failure. When the patent cliff hits, we aren't looking at a dip; we are looking at a structural collapse of a primary revenue pillar.
• Legislative Stroke of a Pen: The Inflation Reduction Act (IRA) and Medicare price negotiations are the "anti-moat." The government is no longer a passive payer; they are now a price-setter. This fundamentally breaks the "charge what the market will bear" model.
• The R&D Treadmill: Pharma is the only business where you must spend billions every year just to avoid shrinking. If the pipeline doesn't produce a "blockbuster" to replace Keytruda, the company becomes a melting ice cube.
• Most Likely Fatality: The combined effect of government price caps and patent expiration within the next 3–7 years. This isn't a cycle; it's a permanent impairment of the margin profile.

💰 Valuation & Margin of Safety

The DCF is sobering. The market is pricing in a growth story that the cash flows don't currently support.

• Intrinsic value estimate: $73.56 per share
• 25% margin of safety entry: $55.17 (Conservative)
• 50% margin of safety entry: $36.78 (Buffett's ideal)
• Current Status: Expensive. Trading significantly above the DCF estimate. The market is paying a premium for "hope" in the pipeline that isn't reflected in the $12.4B FCF.

Verdict: PASS

Price is far too high relative to the conservative intrinsic value of $73.56. The concentration risk in Keytruda and the structural threat of the IRA create too much uncertainty for a "wonderful company at a fair price." We wait for a systemic panic or a deeper valuation reset.